Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. EMEA Innovative Medicine /
      2. How we work /
      3. Collaborations /
      4. Partnering with patient groups

      Partnering with patient groups

      Working with patient advocacy groups (PAGs) deepens our understanding of patients and their needs. This understanding in turn helps us to develop the right medicines and better understanding about our products, so that the medicines we develop are used in the right way.

      Patient organisations play an important role in informing, supporting and assisting patients. As a company, we learn from this interaction, and that helps us in the development of new treatments and in providing useful information.

      The more we can share in the patient journey and learn from each interaction, the better we can serve patients and build solutions.
      Patient with doctor.webp

      How we manage our patient relationships

      It is our goal to ensure that these relationships and partnerships proceed within a principled framework of mutual respect and learning, integrity, independence and transparency.

      Our work with patient advocacy groups (PAGs) fully complies with the EFPIA Code of Practice, adopted by the European Federation of Pharmaceutical Industries and Associations (EFPIA). This code sets the standards for ensuring that relationships between pharmaceutical companies and patient advocacy organisations take place in an ethical and transparent manner. The code can be read in full on the EFPIA website.

      Johnson & Johnson publishes all transfer of value details to patient organisations on its website. In accordance with this code, Johnson & Johnson publishes details of all payments, grants and support given to patient advocacy groups. We are committed to leveraging our contacts with patient groups. This is to help develop treatment paths that suit patient needs better, without compromising ethical business standards.

      Campaigns

      Breaking Depression

      One in four people will be personally affected by mental health problems, such as depression, during their lives. Mental health has been an important part of our heritage since our company was founded and we remain committed to reducing the burden, disability and devastation caused by mental health disorders.

      Breaking Depression is a pan-European awareness campaign aimed at raising awareness of the challenges of living with different types of depression, including major depressive disorder (MDD). Breaking Depression has been initiated by Janssen, with support from the patient-driven Global Alliance of Mental Illness Advocacy Networks-Europe (GAMIAN-Europe).
      Read more

      My IBD Journey campaign

      This is our platform for people looking for practical tips on living with inflammatory bowel disease.

      People living with immune-mediated inflammatory diseases such as IBD can suffer for the rest of their lives, yet the impact of these conditions is dramatically underestimated. As some of these diseases are not readily recognised, people can suffer silently before eventually receiving treatment.

      On this site is a series of short animations providing helpful advice about living well with inflammatory bowel disease (IBD). These animations have been developed in association with the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA).
      Read more

      The pulmonary arterial hypertension (PAH) Patient Charter

      PAH is a rare condition that can affect women, men and children of any age or ethnic background. Only about 15 to 50 people in a million are affected by PAH. This is why many people do not know about the condition. Developed by an international, multidisciplinary steering committee of expert patient advocates and healthcare professionals, the PAH Patient Charter sets out the standards people living with PAH can reasonably expect from their care.
      Learn more

      CP-459038
      September 2024